Description

Irinotecan Medak for infusions 20 mg/ml. 15 ml. (300 mg.)

Ingredients

Active ingredient: Irinotecan hydrochloride trihydrate.

Dosage

Recommended dosage: The recommended dose of Irinotecan Medak for infusions is determined by the patient’s body surface area and general condition. It is administered intravenously over 90 minutes. Dosage adjustments may be needed based on individual patient factors.

Indications

Irinotecan Medak for infusions is indicated for:

• Colorectal cancer
• Small cell lung cancer
• Pancreatic cancer

Contraindications

Do not use Irinotecan Medak for infusions if:

• You are allergic to irinotecan or any other ingredients in the formulation
• You have a history of severe bone marrow suppression
• You have severe diarrhea

Directions

Administration: Irinotecan Medak for infusions should only be administered by healthcare professionals experienced in cancer chemotherapy in a hospital or clinic setting. It is important to follow proper dilution and administration protocols to minimize the risk of adverse effects.

Scientific Evidence

Pharmacological effects: Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication and cell division in cancer cells, leading to cell death. Studies have shown its efficacy in treating various solid tumors, especially colorectal cancer. Research has also highlighted its synergistic effects when used in combination with other chemotherapy agents.

Clinical trials: Clinical trials have demonstrated the effectiveness of Irinotecan in improving progression-free survival and overall survival rates in patients with advanced colorectal cancer. Additionally, studies have shown its tolerability and manageable toxicity profile when used according to recommended dosing schedules.

Overall, Irinotecan Medak for infusions is a valuable treatment option for patients with certain types of cancer, supported by robust scientific evidence and clinical data.

Additional Information

Storage: Store Irinotecan Medak for infusions as per the instructions provided in the packaging. Keep it out of reach of children and away from direct sunlight.

Precautions: It is essential to monitor blood counts and liver function during treatment with Irinotecan to manage potential side effects. Inform your healthcare provider about any existing medical conditions or medications before starting Irinotecan therapy.

In conclusion, Irinotecan Medak for infusions is a well-established chemotherapy drug with proven efficacy in treating various cancers. Its pharmacological action, supported by clinical evidence, makes it a crucial component in the management of cancer patients.